In the preceding three months, 5 analysts have released ratings for 4D Molecular Therapeutics (NASDAQ:FDMT), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 2 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $38.0, a high estimate of $40.00, and a low estimate of $36.00. Highlighting a 10.8% decrease, the current average has fallen from the previous average price target of $42.60.
Exploring Analyst Ratings: An In-Depth Overview
The standing of 4D Molecular Therapeutics among financial experts...
Login or create a forever free account to read this news
Sign up/Log in